Search research articles
Contact Us
Filters
Showing results (551-560 of 563) with videos related to
Page
of 57
Sort By:
World Development
|
February 2, 2024
"People are now working together for a common good": The effect on social capital of participatory design for community-level sanitation infrastructure in urban informal settlements
Allison P Salinger, Isabel Charles, Naomi Francis, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Cardiovascular Research
|
February 18, 2020
Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial
David Corcoran, Aleksandra Radjenovic, Ify R Mordi, et al.
European Journal of Heart Failure
|
December 2, 2017
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF
Ulrik M Mogensen, Lars Køber, Pardeep S Jhund, et al.
Journal of the American College of Cardiology
|
August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF
Jonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure
|
July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial
Mauro Gori, Michele Senni, Brian Claggett, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Plos Genetics
|
October 14, 2010
The genome of a pathogenic rhodococcus: cooptive virulence underpinned by key gene acquisitions
Michal Letek, Patricia González, Iain Macarthur, et al.
JACC. Heart Failure
|
April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
Jonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the American College of Cardiology
|
January 1, 2013
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes
Marco Metra, Gad Cotter, Beth A Davison, et al.
Page
of 57
Search research articles
Search
Showing results (551-560 of 563) with videos related to
Sort By:
Page
of 57
World Development
|
February 2, 2024
"People are now working together for a common good": The effect on social capital of participatory design for community-level sanitation infrastructure in urban informal settlements
Allison P Salinger, Isabel Charles, Naomi Francis, et al.
Circulation. Heart Failure
|
May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Cardiovascular Research
|
February 18, 2020
Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial
David Corcoran, Aleksandra Radjenovic, Ify R Mordi, et al.
European Journal of Heart Failure
|
December 2, 2017
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF
Ulrik M Mogensen, Lars Køber, Pardeep S Jhund, et al.
Journal of the American College of Cardiology
|
August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF
Jonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure
|
July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial
Mauro Gori, Michele Senni, Brian Claggett, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Plos Genetics
|
October 14, 2010
The genome of a pathogenic rhodococcus: cooptive virulence underpinned by key gene acquisitions
Michal Letek, Patricia González, Iain Macarthur, et al.
JACC. Heart Failure
|
April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
Jonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the American College of Cardiology
|
January 1, 2013
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes
Marco Metra, Gad Cotter, Beth A Davison, et al.
Page
of 57